Drug Trial Radar · NCT06987942
Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)
Last checked: Nov 20, 2026Latest source record: May 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
899
Actual
Start
Sep 21, 2024
Primary completion
Nov 15, 2024
Study completion Nov 15, 2024
Sponsor
- Lead sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 7 years, up to 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the immunogenicity of simultaneous administration of varicella live attenuated vaccine (varicella vaccine hereafter) and trivalent inactivated influenza vaccine (TIV hereafter). It will also evaluate the safety of simultaneous administration of the two vaccines. The main questions it aims to answer are: * If geometric mean titer (GMT) of varicella zoster vrius (VZV) antibody in the simultaneous administration group is non-inferior to that in the varicella vaccine separate group. * If GMT of hemagglutination inhibition (HI hereafter) antibody in the simultaneous administration group is non-inferior to that in the TIV separate group. Participants in the simultaneous administration group received a single dose of varicella vaccine and TIV simultaneously on day 0. Participants in the separate groups received a single dose of varicella vaccine or TIV on day 0, respectively.
Conditions
- Varicella
- Influenza Vaccine
Interventions
Varicella vaccine+TIVBiological
* Varicella vaccine: lyophilized powder, subcutaneous injection * TIV: Inactived, split virion, containing H1N1, H3N2 and BV strains.
Varicella vaccineBiological
lyophilized powder, subcutaneous
TIVBiological
Inactived, split virion, containing H1N1, H3N2 and BV strains.
Primary outcomes
What the sponsor says the trial is designed to measure.
- GMT of VZV antibodyTime frame: Day 30 after the vaccination
- GMT of HI antibodyTime frame: Day 30 after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangsu Provincial Center for Disease control and Prevention
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.